Page 24 - Demo

Systemic Sclerosis: Investigations and ManagementInvestigations:%u2022 Anti-Scl 70 antibodies (associated with diffuse form)%u2022 Antinuclear antibodies (ANA) (associated with diffuse form)%u2022 Anti-centromere antibodies (associated with limited form)Management:%u2022 No cure; treatment focuses on symptom management%u2022 Raynaud's phenomenon: calcium channel blockers, phosphodiesterase inhibitors%u2022 Skin manifestations: moisturizers, topical corticosteroids%u2022 Gastrointestinal symptoms: proton pump inhibitors, prokinetics%u2022 Pulmonary hypertension: endothelin receptor antagonists, phosphodiesterase inhibitors%u2022 Immunosuppressants for severe cases: cyclophosphamide, mycophenolate mofetil